India's National Pharmaceutical Pricing Authority has fined Novartis the equivalent of $49 million for overpricing its popular pain drug Voveran, and Novartis has responded by challenging NPPA's authority to do so. The fine is just the latest move in an escalating battle between drugmakers and the NPPA.
Covance has joined forces with Novartis to develop new ways to help drug developers quickly integrate and analyze huge swaths of study data.
Novartis has expanded its relationship with the U.K.'s Oxford BioMedica, signing a deal worth up to $90 million that will support the drugmaker's efforts in CAR-T immunotherapies.
Tuesday, two women pleaded guilty in a Polish court to handing a health fund official a trip worth more than $1,000 in exchange for backing the sale of a certain drug. And one of those women was a Novartis employee, the company said Thursday.
As it works to refine its vaccine strategy for the event of an avian flu pandemic, the NIH is trialing Sanofi's H7N9 vaccine at a range of doses and with a variety of adjuvant combinations. And now, it has one that looks promising.
There's change at the top of a couple of vaccinemakers, with a pair of companies this week announcing upcoming roster moves. For Takeda, that means signing on a new head of vaccine development, while Novartis' vaccine division head will hit the road.
Swiss citizens may have recently voted for some of the world's tightest controls on executive pay. But did that keep the Roche and Novartis pharma chiefs from pocketing more than 13 million Swiss francs ($13.6 million) last year? Not according to a new study.
Six months after announcing a series of deals aimed at refocusing its R&D efforts, Novartis is starting to provide some glimpses of what the new company will look like--and who will and will not be leading it.
Skin plays a big role in day-to-day human interactions, whether it's a handshake or a hug. That doesn't make things so easy for people with chronic spontaneous urticaria or psoriasis.
Novartis is prepping new studies that will test how well three of its oncology drugs--the experimental INC280 and EGF816 and the newly approved ALK inhibitor Zykadia--do when combined with Bristol-Myers Squibb's PD-1 drug nivolumab in a joint attack on non-small cell lung cancer.